BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?

 

 Permissions and Reprints

Abstract

Imatinib, the first-in-class BCR-ABL tyrosine kinase inhibitor (TKI), had been a revolution for the treatment of chronic myeloid leukemia (CML) and had greatly enhanced patient survival. Second- (dasatinib, nilotinib, and bosutinib) and third-generation (ponatinib) TKIs have been developed to be effective against BCR-ABL mutations making imatinib less effective. However, these treatments have been associated with arterial occlusive events. This review gathers clinical data and experiments about the pathophysiology of these arterial occlusive events with BCR-ABL TKIs. Imatinib is associated with very low rates of thrombosis, suggesting a potentially protecting cardiovascular effect of this treatment in patients with BCR-ABL CML. This protective effect might be mediated by decreased platelet secretion and activation, decreased leukocyte recruitment, and anti-inflammatory or antifibrotic effects. Clinical data have guided mechanistic studies toward alteration of platelet functions and atherosclerosis development, which might be secondary to metabolism impairment. Dasatinib, nilotinib, and ponatinib affect endothelial cells and might induce atherogenesis through increased vascular permeability. Nilotinib also impairs platelet functions and induces hyperglycemia and dyslipidemia that might contribute to atherosclerosis development. Description of the pathophysiology of arterial thrombotic events is necessary to implement risk minimization strategies.

• References

• 1 Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol 2013; 4 (02) 103-117
  CrossrefPubMedGoogle Scholar
• 2 Gorre ME, Mohammed M, Ellwood K. , et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293 (5531): 876-880
  CrossrefPubMedGoogle Scholar
• 3 Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology (Am Soc Hematol Educ Program) 2009; 2009 (01) 461-476
  CrossrefPubMedGoogle Scholar
• 4 Cortes JE, Saglio G, Kantarjian HM. , et al. Final 5-year study results of DASISION: the Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol 2016; 34 (20) 2333-2340
  CrossrefPubMedGoogle Scholar
• 5 Hochhaus A, Saglio G, Hughes TP. , et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30 (05) 1044-1054
  CrossrefPubMedGoogle Scholar
• 6 Brümmendorf TH, Cortes JE, de Souza CA. , et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol 2015; 168 (01) 69-81
  CrossrefPubMedGoogle Scholar
• 7 Mealing S, Barcena L, Hawkins N. , et al. The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis. Exp Hematol Oncol 2013; 2 (01) 5
  CrossrefPubMedGoogle Scholar
• 8 Lamontanara AJ, Gencer EB, Kuzyk O, Hantschel O. Mechanisms of resistance to BCR-ABL and other kinase inhibitors. Biochim Biophys Acta 2013; 1834 (07) 1449-1459
  CrossrefPubMedGoogle Scholar
• 9 Pagnano KB, Bendit I, Boquimpani C. , et al; Latin American Leukemia Net (LALNET). BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival. Cancer Invest 2015; 33 (09) 451-458
  CrossrefPubMedGoogle Scholar
• 10 Ursan ID, Jiang R, Pickard EM, Lee TA, Ng D, Pickard AS. Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors. J Manag Care Spec Pharm 2015; 21 (02) 114-122
  PubMedGoogle Scholar
• 11 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 1.2017. 2016
  PubMedGoogle Scholar
• 12 Thanopoulou E, Judson I. The safety profile of imatinib in CML and GIST: long-term considerations. Arch Toxicol 2012; 86 (01) 1-12
  CrossrefPubMedGoogle Scholar
• 13 Kalmanti L, Saussele S, Lauseker M. , et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 2015; 29 (05) 1123-1132
  CrossrefPubMedGoogle Scholar
• 14 Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol 2015; 33 (35) 4210-4218
  CrossrefPubMedGoogle Scholar
• 15 Breccia M, Alimena G. Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development. Expert Opin Drug Saf 2010; 9 (05) 713-721
  CrossrefPubMedGoogle Scholar
• 16 European Medicines Agency. Sprycel - Summary of Product Characteristics 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000709/WC500056998.pdf . Accessed December 22, 2017
  PubMedGoogle Scholar
• 17 European Medicines Agency. Iclusig - Summary of Product Characteristics 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002695/WC500145646.pdf . Accessed December 22, 2017
  PubMedGoogle Scholar
• 18 European Medicines Agency. Tasigna - Summary of Product Characteristics 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000798/WC500034394.pdf . Accessed December 22, 2017
  PubMedGoogle Scholar
• 19 Kantarjian HM, Cortes JE, Kim DW. , et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood 2014; 123 (09) 1309-1318
  CrossrefPubMedGoogle Scholar
• 20 Saglio G, Kim D-W, Issaragrisil S. , et al; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362 (24) 2251-2259
  CrossrefPubMedGoogle Scholar
• 21 Poch Martell M, Sibai H, Deotare U, Lipton JH. Ponatinib in the therapy of chronic myeloid leukemia. Expert Rev Hematol 2016; 9 (10) 923-932
  CrossrefPubMedGoogle Scholar
• 22 Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné JM. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol 2016; DOI: 10.1001/jamaoncol.2015.5932.
  CrossrefPubMedGoogle Scholar
• 23 Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogné JM. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf 2017; 16 (01) 5-12
  CrossrefPubMedGoogle Scholar
• 24 Cortes J, Kim D-W, Pinilla-Ibarz J. , et al. Ponatinib efficacy and safety in heavily pretreated leukemia patients: 3-year results of the PACE trial. 20th Congress of EHA; Copenhagen, Denmark, June 12, 2015
  PubMedGoogle Scholar
• 25 Pasvolsky O, Leader A, Iakobishvili Z, Wasserstrum Y, Kornowski R, Raanani P. Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia. Cardio-Oncology 2015; 1 (01) 5
  PubMedGoogle Scholar
• 26 Gora-Tybor J, Medras E, Calbecka M. , et al. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment. Leuk Lymphoma 2015; 56 (08) 2309-2314
  CrossrefPubMedGoogle Scholar
• 27 le Coutre PD, Hughes TP, Mahon FX. , et al. Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. Leukemia 2016; 30 (07) 1593-1596
  CrossrefPubMedGoogle Scholar
• 28 Sam PY, Ahaneku H, Nogueras-Gonzalez GM. , et al. Cardiovascular events among patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). Blood 2016; 128 (22) 1919
  PubMedGoogle Scholar
• 29 Lassila M, Allen TJ, Cao Z. , et al. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24 (05) 935-942
  CrossrefPubMedGoogle Scholar
• 30 Ma LK, Li Q, He LF. , et al. Imatinib attenuates myocardial fibrosis in association with inhibition of the PDGFRα activity. Arq Bras Cardiol 2012; 99 (06) 1082-1091
  CrossrefPubMedGoogle Scholar
• 31 Fossard G, Blond E, Balsat M. , et al. Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase chronic myelogenous leukemia patients. Haematologica 2016; 101 (03) e86-e90
  CrossrefPubMedGoogle Scholar
• 32 Kostos L, Burbury K, Srivastava G, Prince HM. Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: case report. Platelets 2015; 26 (08) 809-811
  CrossrefPubMedGoogle Scholar
• 33 Mazharian A, Ghevaert C, Zhang L, Massberg S, Watson SP. Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. Blood 2011; 117 (19) 5198-5206
  CrossrefPubMedGoogle Scholar
• 34 Alhawiti N, Burbury KL, Kwa FA. , et al. The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb Res 2016; 145: 54-64
  CrossrefPubMedGoogle Scholar
• 35 Lotfi K, Deb S, Sjöström C, Tharmakulanathan A, Boknäs N, Ramström S. Individual variation in hemostatic alterations caused by tyrosine kinase inhibitors: a way to improve personalized cancer therapy?. Blood 2016; 128 (22) 1908
  CrossrefPubMedGoogle Scholar
• 36 Li R, Grosser T, Diamond SL. Microfluidic whole blood testing of platelet response to pharmacological agents. Platelets 2017; 28 (05) 457-462
  CrossrefPubMedGoogle Scholar
• 37 Senis YA, Mazharian A, Mori J. Src family kinases: at the forefront of platelet activation. Blood 2014; 124 (13) 2013-2024
  CrossrefPubMedGoogle Scholar
• 38 Gratacap MP, Martin V, Valéra MC. , et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009; 114 (09) 1884-1892
  CrossrefPubMedGoogle Scholar
• 39 Albrecht-Schgoer K, Huber K, Grebien F. , et al. Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-induced vasculopathy in CML. Blood 2013; 122 (21) 257
  CrossrefPubMedGoogle Scholar
• 40 Shimabukuro-Vornhagen A, Rothe A, Nogova L, Kochanek M, Scheid C, von Bergwelt-Baildon M. Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report. J Med Case Reports 2011; 5: 215
  CrossrefPubMedGoogle Scholar
• 41 Neelakantan P, Marin D, Laffan M, Goldman J, Apperley J, Milojkovic D. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy. Haematologica 2012; 97 (09) 1444
  CrossrefPubMedGoogle Scholar
• 42 Loren CP, Aslan JE, Rigg RA. , et al. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Thromb Res 2015; 135 (01) 155-160
  CrossrefPubMedGoogle Scholar
• 43 Rivera VM, Pritchard JR, Gonzalvez F, Baker T, Gozgit JM, Hodgson G. Comparative TKI profiling analyses to explore potential mechanisms of Ponatinib-associated arterial thrombotic events. Blood 2014; 124 (21) 1783
  PubMedGoogle Scholar
• 44 Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009; 114 (02) 261-263
  CrossrefPubMedGoogle Scholar
• 45 Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol 2004; 22 (22) 4653-4655
  CrossrefPubMedGoogle Scholar
• 46 Breccia M, Alimena G. The metabolic consequences of imatinib mesylate: changes on glucose, lypidic and bone metabolism. Leuk Res 2009; 33 (07) 871-875
  CrossrefPubMedGoogle Scholar
• 47 Agostino NM, Chinchilli VM, Lynch CJ. , et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 2011; 17 (03) 197-202
  CrossrefPubMedGoogle Scholar
• 48 Breccia M, Muscaritoli M, Cannella L, Stefanizzi C, Frustaci A, Alimena G. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res 2008; 32 (10) 1626-1628
  CrossrefPubMedGoogle Scholar
• 49 Ono K, Suzushima H, Watanabe Y. , et al. Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus. Intern Med 2012; 51 (19) 2763-2766
  CrossrefPubMedGoogle Scholar
• 50 Louvet C, Szot GL, Lang J. , et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 2008; 105 (48) 18895-18900
  CrossrefPubMedGoogle Scholar
• 51 Hägerkvist R, Jansson L, Welsh N. Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin Sci (Lond) 2008; 114 (01) 65-71
  CrossrefPubMedGoogle Scholar
• 52 Han MS, Chung KW, Cheon HG. , et al. Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice. Diabetes 2009; 58 (02) 329-336
  CrossrefPubMedGoogle Scholar
• 53 Hägerkvist R, Makeeva N, Elliman S, Welsh N. Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro. Cell Biol Int 2006; 30 (12) 1013-1017
  CrossrefPubMedGoogle Scholar
• 54 Hägerkvist R, Sandler S, Mokhtari D, Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J 2007; 21 (02) 618-628
  CrossrefPubMedGoogle Scholar
• 55 Xia CQ, Zhang P, Li S. , et al. C-Abl inhibitor imatinib enhances insulin production by β cells: c-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2. PLoS One 2014; 9 (05) e97694
  CrossrefPubMedGoogle Scholar
• 56 Sadiq S, Owen E, Foster T. , et al. Nilotinib-induced metabolic dysfunction: insights from a translational pilot study using in vitro adipocyte models and patient cohorts. 22nd EHA congress; June 22–25, 2017; Madrid, Spain
  PubMedGoogle Scholar
• 57 Iizuka K, Niwa H, Kato T, Takeda J. Dasatinib improves insulin sensitivity and affects lipid metabolism in a patient with chronic myeloid leukaemia. BMJ Case Rep 2016; 2016: 201
  PubMedGoogle Scholar
• 58 Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC. Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?. J Clin Endocrinol Metab 2010; 95 (08) 3763-3767
  CrossrefPubMedGoogle Scholar
• 59 Hosch SE, Olefsky JM, Kim JJ. APPLied mechanics: uncovering how adiponectin modulates insulin action. Cell Metab 2006; 4 (01) 5-6
  CrossrefPubMedGoogle Scholar
• 60 Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005; 6 (01) 13-21
  CrossrefPubMedGoogle Scholar
• 61 Fitter S, Vandyke K, Gronthos S, Zannettino AC. Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. J Mol Endocrinol 2012; 48 (03) 229-240
  CrossrefPubMedGoogle Scholar
• 62 Aichberger KJ, Herndlhofer S, Schernthaner GH. , et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011; 86 (07) 533-539
  CrossrefPubMedGoogle Scholar
• 63 Breccia M, Muscaritoli M, Gentilini F. , et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res 2007; 31 (12) 1770-1772
  CrossrefPubMedGoogle Scholar
• 64 Castagnetti F, Breccia M, Gugliotta G. , et al; GIMEMA CML Working Party. Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. Haematologica 2016; 101 (10) 1200-1207
  CrossrefPubMedGoogle Scholar
• 65 Delphine R, Gautier J-f, Breccia M. , et al. Incidence of hyperglycemia by 3 years in patients (Pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd. Blood 2012; 120 (21) 1686
  PubMedGoogle Scholar
• 66 Iurlo A, Orsi E, Cattaneo D. , et al. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?. Oncotarget 2015; 6 (32) 33944-33951
  PubMedGoogle Scholar
• 67 Racil Z, Razga F, Drapalova J. , et al. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica 2013; 98 (10) e124-e126
  CrossrefPubMedGoogle Scholar
• 68 Ito Y, Miyamoto T, Chong Y, Maki T, Akashi K, Kamimura T. Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin. Int J Hematol 2013; 97 (01) 135-138
  CrossrefPubMedGoogle Scholar
• 69 Hadzijusufovic E, Herndlhofer S, Aichberger KJ. , et al. Nilotinib exerts direct effects on vascular endothelial cells and may act as a co-trigger of atherosclerosis in patients with Ph+ CML. Blood 2011; 118 (21) 2753
  PubMedGoogle Scholar
• 70 Breccia M, Loglisci G, Salaroli A, Serrao A, Alimena G. Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index. Leuk Res 2012; 36 (04) e66-e67
  CrossrefPubMedGoogle Scholar
• 71 Saglio G, Larson RA, Hughes TP. , et al. Efficacy and safety of Nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (Pts) with type 2 diabetes in the ENESTnd trial. Blood 2010; 116 (21) 3430
  PubMedGoogle Scholar
• 72 Frasca F, Pandini G, Malaguarnera R. , et al. Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling. J Biol Chem 2007; 282 (36) 26077-26088
  CrossrefPubMedGoogle Scholar
• 73 Franceschino A, Tornaghi L, Benemacher V, Assouline S, Gambacorti-Passerini C. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. Haematologica 2008; 93 (02) 317-318
  CrossrefPubMedGoogle Scholar
• 74 Gottardi M, Manzato E, Gherlinzoni F. Imatinib and hyperlipidemia. N Engl J Med 2005; 353 (25) 2722-2723
  CrossrefPubMedGoogle Scholar
• 75 Gologan R, Constantinescu G, Georgescu D. , et al. Hypolipemiant besides antileukemic effect of imatinib mesylate. Leuk Res 2009; 33 (09) 1285-1287
  CrossrefPubMedGoogle Scholar
• 76 Ellis M, Krashin E, Hamburger-Avnery O, Gan S, Elis A, Ashur-Fabian O. The anti-leukemic and lipid lowering effects of imatinib are not hindered by statins in CML: a retrospective clinical study and in vitro assessment of lipid-genes transcription. Leuk Lymphoma 2017; 58 (05) 1172-1177
  CrossrefPubMedGoogle Scholar
• 77 Franklin M, Burns L, Perez S, Yerragolam D, Makenbaeva D. Incidence of type II diabetes mellitus and hyperlipidemia in patients prescribed Dasatinib or Nilotinib as first or second line therapy for chronic myelogenous leukemia (CML). Blood 2016; 128 (22) 4766
  PubMedGoogle Scholar
• 78 Rea D, Mirault T, Cluzeau T. , et al. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica 2014; 99 (07) 1197-1203
  CrossrefPubMedGoogle Scholar
• 79 Maurizot A, Beressi JP, Manéglier B. , et al. Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion. Blood Cancer J 2014; 4: e247
  CrossrefPubMedGoogle Scholar
• 80 Breccia M, Molica M, Alimena G. How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review. Leuk Res 2014; 38 (12) 1392-1398
  CrossrefPubMedGoogle Scholar
• 81 Venalis P, Maurer B, Akhmetshina A. , et al. Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo. J Cell Mol Med 2009; 13 (10) 4185-4191
  CrossrefPubMedGoogle Scholar
• 82 Gover-Proaktor A, Granot G, Shapira S. , et al. Ponatinib reduces viability, migration, and functionality of human endothelial cells. Leuk Lymphoma 2017; 58 (06) 1455-1467
  CrossrefPubMedGoogle Scholar
• 83 Vallières K, Petitclerc E, Laroche G. On the ability of imatinib mesylate to inhibit smooth muscle cell proliferation without delaying endothelialization: an in vitro study. Vascul Pharmacol 2009; 51 (01) 50-56
  CrossrefPubMedGoogle Scholar
• 84 Hacker TA, Griffin MO, Guttormsen B, Stoker S, Wolff MR. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo. J Invasive Cardiol 2007; 19 (06) 269-274
  PubMedGoogle Scholar
• 85 Vrekoussis T, Stathopoulos EN, De Giorgi U. , et al. Modulation of vascular endothelium by imatinib: a study on the EA.hy 926 endothelial cell line. J Chemother 2006; 18 (01) 56-65
  CrossrefPubMedGoogle Scholar
• 86 Letsiou E, Rizzo AN, Sammani S. , et al. Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2015; 308 (03) L259-L269
  CrossrefPubMedGoogle Scholar
• 87 Guignabert C, Phan C, Seferian A. , et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest 2016; 126 (09) 3207-3218
  CrossrefPubMedGoogle Scholar
• 88 Rizzo AN, Sammani S, Esquinca AE. , et al. Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2015; 309 (11) L1294-L1304
  CrossrefPubMedGoogle Scholar
• 89 Katgı A, Sevindik ÖG, Gökbulut AA. , et al. Nilotinib does not alter the secretory functions of carotid artery endothelial cells in a prothrombotic or antithrombotic fashion. Clin Appl Thromb Hemost 2015; 21 (07) 678-683
  CrossrefPubMedGoogle Scholar
• 90 Hadzijusufovic E, Kirchmair R, Theurl M. , et al. Ponatinib exerts multiple effects on vascular endothelial cells: possible mechanisms and explanations for the adverse vascular events seen in CML patients treated with Ponatinib. Blood 2016; 128 (22) 1883
  PubMedGoogle Scholar
• 91 Lorenzi M, Cagliero E, Toledo S. Glucose toxicity for human endothelial cells in culture. Delayed replication, disturbed cell cycle, and accelerated death. Diabetes 1985; 34 (07) 621-627
  CrossrefPubMedGoogle Scholar
• 92 Shah NP, Wallis N, Farber HW. , et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol 2015; 90 (11) 1060-1064
  CrossrefPubMedGoogle Scholar
• 93 Frost AE, Barst RJ, Hoeper MM. , et al. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant 2015; 34 (11) 1366-1375
  CrossrefPubMedGoogle Scholar
• 94 Dasgupta SK, Le A, Vijayan KV, Thiagarajan P. Dasatinib inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoA-ROCK pathway. Cancer Med 2017; 6 (04) 809-818
  CrossrefPubMedGoogle Scholar
• 95 Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia 2003; 17 (09) 1713-1721
  CrossrefPubMedGoogle Scholar
• 96 Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, Dibb NJ. Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia 2009; 23 (03) 590-594
  CrossrefPubMedGoogle Scholar
• 97 Dewar AL, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the functional capacity of cultured human monocytes. Immunol Cell Biol 2005; 83 (01) 48-56
  CrossrefPubMedGoogle Scholar
• 98 Dewar AL, Cambareri AC, Zannettino ACW. , et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005; 105 (08) 3127-3132
  CrossrefPubMedGoogle Scholar
• 99 Metharom P, Martin K, Kumar AH. , et al. Pleiotropic role for monocyte C-fms protein in response to vascular injury: potential therapeutic target. Atherosclerosis 2011; 216 (01) 74-82
  CrossrefPubMedGoogle Scholar
• 100 Gacic J, Vorkapic E, Olsen RS. , et al. Imatinib reduces cholesterol uptake and matrix metalloproteinase activity in human THP-1 macrophages. Pharmacol Rep 2016; 68 (01) 1-6
  CrossrefPubMedGoogle Scholar
• 101 Cwynarski K, Laylor R, Macchiarulo E. , et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18 (08) 1332-1339
  CrossrefPubMedGoogle Scholar
• 102 Brownlow N, Russell AE, Saravanapavan H. , et al. Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Leukemia 2008; 22 (03) 649-652
  CrossrefPubMedGoogle Scholar
• 103 Ozanne J, Prescott AR, Clark K. The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases. Biochem J 2015; 465 (02) 271-279
  CrossrefPubMedGoogle Scholar
• 104 Darling NJ, Toth R, Arthur JS, Clark K. Inhibition of SIK2 and SIK3 during differentiation enhances the anti-inflammatory phenotype of macrophages. Biochem J 2017; 474 (04) 521-537
  CrossrefPubMedGoogle Scholar
• 105 Schade AE, Schieven GL, Townsend R. , et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111 (03) 1366-1377
  PubMedGoogle Scholar
• 106 Blake SJ, Lyons AB, Hughes TP. Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro. J Cell Mol Med 2009; 13 (03) 599-601
  CrossrefPubMedGoogle Scholar
• 107 Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008; 127 (03) 330-339
  CrossrefPubMedGoogle Scholar
• 108 Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, Bijlmakers MJ. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia 2010; 24 (04) 896-900
  CrossrefPubMedGoogle Scholar
• 109 Farha S, Dweik R, Rahaghi F. , et al. Imatinib in pulmonary arterial hypertension: c-Kit inhibition. Pulm Circ 2014; 4 (03) 452-455
  CrossrefPubMedGoogle Scholar
• 110 Juurikivi A, Sandler C, Lindstedt KA. , et al. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis 2005; 64 (08) 1126-1131
  CrossrefPubMedGoogle Scholar
• 111 Sun YL, Kumar P, Sodani K. , et al. Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. Oncol Rep 2014; 31 (04) 1605-1612
  CrossrefPubMedGoogle Scholar
• 112 Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 2010; 30 (02) 139-143
  CrossrefPubMedGoogle Scholar
• 113 Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 2006; 69 (05) 1527-1533
  CrossrefPubMedGoogle Scholar
• 114 Nakamura K, Akagi S, Ogawa A. , et al. Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 2012; 159 (02) 100-106
  CrossrefPubMedGoogle Scholar
• 115 Li L, Blumenthal DK, Masaki T, Terry CM, Cheung AK. Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells. J Cell Biochem 2006; 99 (06) 1553-1563
  CrossrefPubMedGoogle Scholar
• 116 Rocha A, Azevedo I, Soares R. Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells. Angiogenesis 2007; 10 (04) 279-286
  CrossrefPubMedGoogle Scholar
• 117 Ballinger ML, Osman N, Hashimura K. , et al. Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo. J Cell Mol Med 2010; 14 (6B): 1408-1418
  PubMedGoogle Scholar
• 118 Distler JH, Jüngel A, Huber LC. , et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56 (01) 311-322
  CrossrefPubMedGoogle Scholar
• 119 Yoshiji H, Noguchi R, Kuriyama S. , et al. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 2005; 288 (05) G907-G913
  CrossrefPubMedGoogle Scholar
• 120 Salhotra A, Tsai N, Thomas SH. , et al. Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2015; 50 (01) 139-141
  CrossrefPubMedGoogle Scholar
• 121 Makiyama Y, Toba K, Kato K. , et al. Imatinib mesilate inhibits neointimal hyperplasia via growth inhibition of vascular smooth muscle cells in a rat model of balloon injury. Tohoku J Exp Med 2008; 215 (04) 299-306
  CrossrefPubMedGoogle Scholar
• 122 Park D, Kim SM, Min SI, Ha J, Kim IG, Min SK. Inhibition of intimal hyperplasia by local perivascular application of rapamycin and imatinib mesilate after carotid balloon injury. J Korean Surg Soc 2013; 85 (06) 296-301
  CrossrefPubMedGoogle Scholar
• 123 Leppänen O, Rutanen J, Hiltunen MO. , et al. Oral imatinib mesylate (STI571/Gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits. Circulation 2004; 109 (09) 1140-1146
  CrossrefPubMedGoogle Scholar
• 124 Sevim KZ, Silistreli O, Gorgu M, Sevim O, Ergur B. Short-term vasculoprotective effects of imatinib mesylate on intimal hyperplasia of arterial anastomosis: An experimental study using a rabbit model. Can J Plast Surg 2012; 20 (04) 223-228
  CrossrefPubMedGoogle Scholar
• 125 Wu J, Chen Z, Bhalla KN. Treatment of restenosis and stenosis with dasatinib (2014). USF Patents. 152
  PubMedGoogle Scholar
• 126 Sánchez-Ortega I, Servitje O, Arnan M. , et al. Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012; 18 (02) 318-323
  CrossrefPubMedGoogle Scholar
• 127 Marinelli Busilacchi E, Olivieri J, Viola N. , et al. The exaggerated collagen expression in Gvhd-fibroblasts is effectively inhibited by therapeutic concentration of Nilotinib. Blood 2016; 128 (22) 4597
  PubMedGoogle Scholar
• 128 Shiha GE, Abu-Elsaad NM, Zalata KR, Ibrahim TM. Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: an insight. Clin Exp Pharmacol Physiol 2014; 41 (10) 788-797
  CrossrefPubMedGoogle Scholar
• 129 Giles FJ, O'Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009; 23 (10) 1698-1707
  CrossrefPubMedGoogle Scholar
• 130 Rix U, Hantschel O, Dürnberger G. , et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110 (12) 4055-4063
  CrossrefPubMedGoogle Scholar
• 131 Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 2004; 104 (07) 1931-1939
  CrossrefPubMedGoogle Scholar
• 132 Bantscheff M, Eberhard D, Abraham Y. , et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007; 25 (09) 1035-1044
  CrossrefPubMedGoogle Scholar
• 133 Weisberg E, Manley PW, Breitenstein W. , et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7 (02) 129-141
  CrossrefPubMedGoogle Scholar
• 134 Buchdunger E, Cioffi CL, Law N. , et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295 (01) 139-145
  PubMedGoogle Scholar
• 135 Manley PW, Drueckes P, Fendrich G. , et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010; 1804 (03) 445-453
  CrossrefPubMedGoogle Scholar
• 136 Fabian MA, Biggs III WH, Treiber DK. , et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23 (03) 329-336
  CrossrefPubMedGoogle Scholar
• 137 Shi H, Zhang CJ, Chen GY, Yao SQ. Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes. J Am Chem Soc 2012; 134 (06) 3001-3014
  CrossrefPubMedGoogle Scholar
• 138 Liu Y, Wang Z, Kwong SQ. , et al. Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol 2011; 55 (03) 612-625
  CrossrefPubMedGoogle Scholar
• 139 Sakamoto A, Sugamoto Y, Tokunaga Y. , et al. Expression profiling of the ephrin (EFN) and Eph receptor (EPH) family of genes in atherosclerosis-related human cells. J Int Med Res 2011; 39 (02) 522-527
  CrossrefPubMedGoogle Scholar
• 140 Khan AA, Sandhya VK, Singh P. , et al. Signaling network map of endothelial TEK tyrosine kinase. J Signal Transduct 2014; 2014: 173026
  PubMedGoogle Scholar
• 141 Chislock EM, Ring C, Pendergast AM. Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival. Proc Natl Acad Sci U S A 2013; 110 (30) 12432-12437
  CrossrefPubMedGoogle Scholar
• 142 Boulanger CM, Loyer X, Rautou PE, Amabile N. Extracellular vesicles in coronary artery disease. Nat Rev Cardiol 2017; 14 (05) 259-272
  CrossrefPubMedGoogle Scholar
• 143 Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag 2017; 13: 293-303
  CrossrefPubMedGoogle Scholar
• 144 Damrongwatanasuk R, Fradley MG. Cardiovascular complications of targeted therapies for chronic myeloid leukemia. Curr Treat Options Cardiovasc Med 2017; 19 (04) 24
  CrossrefPubMedGoogle Scholar
• 145 Valent P, Hadzijusufovic E, Hoermann G. , et al. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res 2017; 59: 47-54
  CrossrefPubMedGoogle Scholar
• 146 García-Gutiérrez V, Jiménez-Velasco A, Gómez-Casares MT, Sánchez-Guijo F, López-Sendón JL, Steegmann Olmedillas JL. [Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting]. Med Clin (Barc) 2016; 146 (12) 561.e1-561.e8
  CrossrefPubMedGoogle Scholar
• 147 Aman J, van Bezu J, Damanafshan A. , et al. Effective treatment of edema and endothelial barrier dysfunction with imatinib. Circulation 2012; 126 (23) 2728-2738
  CrossrefPubMedGoogle Scholar
• 148 Kim SR, Suh W. Beneficial effects of the Src inhibitor, dasatinib, on breakdown of the blood-retinal barrier. Arch Pharm Res 2017; 40 (02) 197-203
  CrossrefPubMedGoogle Scholar
• 149 Sukegawa M, Wang X, Nishioka C. , et al. The BCR/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1β in vascular endothelium in association with downregulation of miR-3p. Leuk Res 2017; 58: 83-90
  CrossrefPubMedGoogle Scholar
• 150 Wolf AM, Wolf D, Rumpold H. , et al. The kinase inhibitor imatinib mesylate inhibits TNF-alpha production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci U S A 2005; 102 (38) 13622-13627
  CrossrefPubMedGoogle Scholar
• 151 Fraser CK, Lousberg EL, Kumar R, Hughes TP, Diener KR, Hayball JD. Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo. Exp Hematol 2009; 37 (12) 1435-1444
  CrossrefPubMedGoogle Scholar
• 152 Seggewiss R, Loré K, Greiner E. , et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105 (06) 2473-2479
  CrossrefPubMedGoogle Scholar
• 153 Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104 (04) 1094-1099
  CrossrefPubMedGoogle Scholar
• 154 Chen J, Schmitt A, Chen B. , et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med 2008; 12 (5B): 2107-2118
  CrossrefPubMedGoogle Scholar
• 155 Perros F, Montani D, Dorfmüller P. , et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178 (01) 81-88
  CrossrefPubMedGoogle Scholar
• 156 Canning P, Tan L, Chu K, Lee SW, Gray NS, Bullock AN. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors. J Mol Biol 2014; 426 (13) 2457-2470
  CrossrefPubMedGoogle Scholar
• 157 Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008; 49 (04) 615-619
  CrossrefPubMedGoogle Scholar
• 158 Remsing Rix LL, Rix U, Colinge J. , et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009; 23 (03) 477-485
  CrossrefPubMedGoogle Scholar
• 159 Green MR, Newton MD, Fancher KM. Off-Target Effects of BCR-ABL and JAK2 Inhibitors. Am J Clin Oncol 2016; 39 (01) 76-84
  CrossrefPubMedGoogle Scholar

• Supplementary Material